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Gupta S, Berry JD, Ayers CR, Peshock RM, Khera A, de Lemos JA, Patel PC, Markham DW,
Drazner MH. Left Ventricular Hypertrophy, Aortic Wall Thickness, and Lifetime Predicted Risk of
Cardiovascular Disease: The Dallas Heart Study. J Am Coll Cardiol Img 2010;3:605–13.
Please note that Figure 3 was inadvertently printed incorrectly. The correct figure and legend are printed
below.
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Figure 3. Prevalent Subclinical CVD Stratiﬁed by the Predicted Risk and Method of Indexing LV Mass
Men (A) and women (B). To assess prevalent LVH, LV mass was indexed to fat-free mass, BSA, and height2.7. Subclinical CVD included the
presence of LVH, detectable CAC, or AWT 75th percentile. †p  0.01; ‡p  0.001. Other abbreviations as in Figure 1.
